

# **HHS Public Access**

Author manuscript *Cell Rep.* Author manuscript; available in PMC 2023 March 21.

Published in final edited form as:

Cell Rep. 2023 January 31; 42(1): 112018. doi:10.1016/j.celrep.2023.112018.

## Neddylation is required for perinatal cardiac development through stimulation of metabolic maturation

Jianqiu Zou<sup>1</sup>, Wenjuan Wang<sup>1,2</sup>, Yi Lu<sup>1,3</sup>, Juan Ayala<sup>1</sup>, Kunzhe Dong<sup>4</sup>, Hongyi Zhou<sup>5</sup>, Jinxi Wang<sup>6</sup>, Weiqin Chen<sup>5</sup>, Neal L. Weintraub<sup>1</sup>, Jiliang Zhou<sup>6</sup>, Jie Li<sup>1,7</sup>, Huabo Su<sup>1,4,8,\*</sup> <sup>1</sup>Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA

<sup>2</sup>Key Laboratory of Protein Modification and Degradation, State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, Guangdong 511436, China

<sup>3</sup>Department of Neurology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China

<sup>4</sup>Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA

<sup>5</sup>Department of Physiology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA

<sup>6</sup>Department of Medicine, University of Iowa, 200 Hawkins Drive, CBRB 2270B, Iowa City, IA 52242, USA

<sup>7</sup>Division of Cardiology, Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA

<sup>8</sup>Lead contact

## SUMMARY

Cardiac maturation is crucial for postnatal cardiac development and is increasingly known to be regulated by a series of transcription factors. However, post-translational mechanisms regulating this process remain unclear. Here we report the indispensable role of neddylation in cardiac maturation. Mosaic deletion of NAE1, an essential enzyme for neddylation, in neonatal hearts results in the rapid development of cardiomyopathy and heart failure. NAE1 deficiency

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

<sup>\*</sup>Correspondence: hsu@augusta.edu.

AUTHOR CONTRIBUTIONS

J. Zou and H.S. conceptualized the project and designed the experiments. J. Zou, K.D., H.Z., J.W., W.C., J.L., and H.S. performed the analysis of the data; J. Zou, W.W., Y.L., J.A., H.Z., and J.L. performed the experiments; W.C., N.L.W., J. Zhou, J.L., and H.S. provided resources; J. Zou and H.S. wrote the original draft and the final version of the manuscript; W.C., N.L.W., J. Zhou, and J.L. wrote, reviewed, and edited the manuscript; H.S. supervised the project. All authors read and approved the final paper.

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.celrep.2023.112018.

DECLARATION OF INTERESTS

The authors declare no competing interests.

disrupts transverse tubule formation, inhibits physiological hypertrophy, and represses fetal-toadult isoform switching, thus culminating in cardiomyocyte immaturation. Mechanistically, we find that neddylation is needed for the perinatal metabolic transition from glycolytic to oxidative metabolism in cardiomyocytes. Further, we show that HIF1a is a putative neddylation target and that inhibition of neddylation accumulates HIF1a and impairs fatty acid utilization and bioenergetics in cardiomyocytes. Together, our data show neddylation is required for cardiomyocyte maturation through promoting oxidative metabolism in the developing heart.

## Graphical abstract



### In brief

Zou et al. investigate the role of neddylation, a protein modification process, in the development and maturation of the heart during the perinatal stage. The results suggest that neddylation plays a crucial role in heart cell maturation and postnatal cardiac development by regulating the switch between glycolysis and oxidative metabolism.

## INTRODUCTION

During development, the heart undergoes a series of profound structural, morphological, and functional changes until it ultimately develops into a functionally competent adult organ. From midgestation to adulthood, terminally differentiated cardiomyocytes (CMs) undergo progressive maturation processes, including sarcomeric protein isoform

switching, transverse-tubule network development, electrophysiological maturation, cellcycle withdrawal, hypertrophic growth, and metabolic reprogramming.<sup>1,2</sup> Disruption of these critical maturation processes can lead to congenital heart disease or predisposition to cardiomyopathies and heart failure in adult life,<sup>3–6</sup> emphasizing the significance of CM maturation in cardiac physiology and disease. Importantly, knowledge gained from cardiac maturation research might help to optimize approaches to promote the maturation of induced pluripotent stem cell (iPSC)-derived CMs used in cardiac regenerative medicine.<sup>7</sup> Therefore, there is broad interest in understanding the regulatory mechanisms that underpin CM maturation.

Cardiac maturation involves crucial metabolic reprogramming during the transition from the fetal to the postnatal stage. Fetal hearts rely predominantly on glycolysis to generate ATP due to the hypoxic environment. In response to increased oxygen tension and altered nutrition sources postpartum, perinatal hearts primarily utilize fatty acid oxidation to meet their rapidly increased energy demands, which persists throughout life.<sup>8</sup> This metabolic maturation is accompanied by the expansion of mitochondrial number and size,<sup>9</sup> densification of mitochondrial cristae,<sup>10</sup> upregulation of genes involved in fatty acid metabolism and oxidative phosphorylation,<sup>11</sup> and downregulation of glycolytic genes.<sup>12</sup> Perturbation of the developmental metabolic shift has been shown to cause heart failure and perinatal lethality in mouse models<sup>13–17</sup> and in humans,<sup>18</sup> highlighting a critical need to understand the upstream mechanisms governing this process. Over the past decade, considerable progress has been made in uncovering transcriptional regulators crucial for CM metabolic maturation, including hypoxia-inducible factor  $1\alpha$  (HIF1 $\alpha$ ),<sup>6</sup> estrogen-related receptors a and  $\gamma$  (ERRa and ERR $\gamma$ ),<sup>19</sup> and the peroxisome proliferator-activated receptor  $\gamma$  coactivator 1a/ $\beta$ /peroxisome proliferator-activated receptor (PGC1a/ $\beta$ /PPAR) axis.<sup>5,14</sup> In particular, downregulation of HIF1a-mediated hypoxic signaling appears to be an important physiological switch driving metabolic reprogramming during cardiac maturation.<sup>6,20</sup> While HIF1a is highly expressed in fetal hearts and is essential for embryonic heart development by sustaining CM proliferation,<sup>21</sup> its level rapidly decreases from day 14.5 in murine embryonic hearts<sup>6</sup> and after birth.<sup>17,22</sup> and persistent activation of HIF1 $\alpha$  in perinatal hearts impairs metabolic reprogramming, leading to heart failure and perinatal lethality.<sup>6,20</sup>

In addition to transcriptional mechanisms, posttranslational modifications (PTMs) provide another layer of regulation for cells to regulate diverse cellular processes. In eukaryotic cells, proteins are subjected to over 300 PTMs in response to external physical or chemical stimuli, which significantly expand the diversity of the proteome. PTMs result in rapid changes in protein conformation, subcellular localization, assembly/disassembly of multiple protein complexes, and binding affinity to DNA and proteins. By doing so, PTMs can subtly or dramatically alter protein activity and function without triggering *de novo* protein synthesis at the transcriptional level, thereby saving energy and material resources. Despite the increasing appreciation of PTMs, such as phosphorylation, methylation, acetylation, O-GlcNAcylation, ubiquitination, and SUMOylation, in cardiac development and pathophysiology,<sup>23–26</sup> many more known PTMs remain to be investigated in heart tissues.

Neural precursor cell expressed, developmentally downregulated 8 (NEDD8) is a ubiquitinlike protein that covalently modifies target proteins in a way analogous to ubiquitination.<sup>27</sup> Conjugation of NEDD8 to target proteins, termed neddylation, is catalyzed by a NEDD8specific E1-E2-E3 enzyme system and can be reversed by NEDD8 proteases.<sup>28–30</sup> By modulating the function of its various substrates, such as cullin proteins, neddylation regulates diverse cellular processes and multiple pathophysiological states, such as tumorigenesis,<sup>31</sup> metabolic disorders,<sup>32</sup> liver dysfunction,<sup>33</sup> and neural development.<sup>34,35</sup> We previously demonstrated that an intact NEDD8 pathway is essential for cardiac homeostasis in adulthood, 36-39 and dysregulation of neddylation is associated with cardiomyopathies in human and murine hearts.<sup>40</sup> More recently, we reported that neddylation is downregulated in the developing mouse heart after postnatal day 7, a time window when CMs start exiting the cell cycle.<sup>41</sup> Deletion of NEDD8-activating enzyme 1 (NAE1), a regulatory subunit of the only NEDD8 E1 that is essential for NEDD8 activation and conjugation, in the developing heart via a MHC<sup>Cre</sup> causes ventricular non-compaction and heart failure, which is at least in part attributable to inactivation of Yes-associated protein (YAP) signaling and CM proliferation arrest.<sup>41</sup> While these findings demonstrate a critical role for neddylation in cardiac chamber development in embryonic hearts, the downregulation of neddylation in postnatal hearts drove us to determine whether neddylation is dispensable for postnatal cardiac development and whether neddylation has a role beyond regulating CM proliferation.

In this report, we describe a series of studies designed to determine the role of neddylation in postnatal hearts. Using strategies to conditionally delete the gene encoding NAE1 in mice, we demonstrate that neddylation is necessary for proper control of CM metabolic transition and for normal peri- and postnatal cardiac maturation. Furthermore, we identify that neddylation is required to suppress HIF1a signaling by directly modifying HIF1a and its ubiquitin ligase cullin 2 (Cul2).

## RESULTS

#### Postnatal deletion of NAE1 induces dilated cardiomyopathy and heart failure

Perinatal lethality of  $\alpha$ MHC<sup>Cre</sup>-driven NAE1 knockout<sup>41</sup> prevents using this mouse line to investigate the role of neddylation in postnatal cardiac development. We employed adeno-associated virus 9 (AAV9) expressing Cre recombinase under the control of the cardiac troponin T (cTnT) promoter<sup>42</sup> to generate mosaic cardiac-specific NAE1 knockout mice. The AAV-Cre was injected into neonatal NAE1<sup>F/+</sup> and NAE1<sup>F/F</sup> mice carrying a lineage-tracing reporter Rosa26<sup>mTmG</sup> allele<sup>43</sup> (Figure 1A), which labels Cre-expressing cells with membrane-bound GFP (mG) and non-expressing cells with membrane-bound Tomato (mT) (Figures 1B and S1A). High-dose AAV-Cre (5 × 10<sup>11</sup> viral genome copies [GC]/pup) transduced about 80% of CMs and significantly reduced NAE1 transcripts and proteins, leading to a significant decrease in total neddylated proteins and neddylated Cul2, a well-known NEDD8 substrate, in NAE1<sup>F/F</sup> hearts compared with NAE1<sup>F/+</sup> littermates (Figures 1D–1F), confirming inhibition of neddylation. Cardiac phenotypes of these mice were characterized by temporal echocardiography and morphological and gravimetric analyses. Compared with littermate NAE1<sup>F/+</sup> mice, high-dose AAV-Cre induced progressive

dilated cardiomyopathy and eventually heart failure in NAE1<sup>F/F</sup> mice by 6 weeks of age, evidenced by enlarged heart size, increased heart weight-to-body weight and lung weightto-body weight ratios, increased left-ventricular chamber size, reduced left-ventricular wall thickness, and gradually deteriorating left-ventricular ejection fraction and fractional shortening (Figures 1G–1K). Quantitative real-time PCR demonstrated the upregulation of the cardiac stress markers *Nppa* and *Nppb* and the downregulation of *Serca2a* (Figure 1D). Histological analyses showed enlarged heart size and prominent cardiac fibrosis in NAE1<sup>F/F</sup> hearts (Figures S1B and S1C). Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining, Evans blue dye (EBD) infiltration assay, and immunoblotting of cleaved caspase 3 did not identify evidence of pronounced CM cell death in 4- and 6-week-old NAE1<sup>F/F</sup> hearts (Figures S1D–S1F). Taken together, these data demonstrate that neddylation is indispensable for normal postnatal cardiac development.

#### **Deletion of NAE1 impairs CM maturation**

Since the deletion of NAE1 occurred in the critical time window of CM maturation, we hypothesized that disruption of CM maturation underlies the pathogenesis of cardiomyopathy in NAE1<sup>F/F</sup> hearts receiving high-dose AAV-Cre. To rule out confounding effects secondary to pathological cardiac remodeling, we titrated AAV-Cre doses, which led to detection of Cre activity in ~60% and 40% of CMs at medium ( $0.5 \times 10^{11}$  viral GC/pup) and low ( $0.25 \times 10^{11}$  viral GC/pup) doses, respectively (Figure 1C). Neither dose caused discernible cardiac remodeling in NAE1<sup>F/F</sup> mice, evidenced by comparable fibrotic areas, cardiac morphometric parameters, ejection fraction, and left-ventricular mass measured by echocardiography between NAE1<sup>F/F</sup> and NAE1<sup>F/+</sup> mice at 4 weeks of age (Figures S1G and S1H). Thus, these hearts were used to assess the impact of NAE1 deletion on CM maturation.

To visualize T-tubule organization in live CMs in situ, we labeled T tubules with the plasma membrane dye FM 4-64FX through retrograde heart perfusion and performed in situ confocal imaging.<sup>44</sup> We observed the T tubules to be drastically disorganized in mG<sup>+</sup> CMs in NAE1<sup>F/F</sup> hearts infected with low-dose AAV-Cre, while those in neighboring mT<sup>+</sup> CMs remained well aligned (Figure 2A). Quantification of FM 4-64FX fluorescence intensity showed a significant reduction in T-tubule contents in mG<sup>+</sup> CMs vs. mT<sup>+</sup> CMs (Figure 2C). Interestingly, we noted that the mG and mT signals perfectly matched those of FM 4-64FX (Figure 2B), likely due to the membrane-targeting sequence. Immunostaining of the T-tubule protein junctophilin-2 (JPH2) further confirmed that both mT and mG colocalize with JPH2 (Figures S2A and S2B), suggesting that the mT/mG reporter faithfully traces the T-tubule network. Examining mT/mG patterns in 4-week-old NAE1<sup>F/+</sup> and NAE1<sup>F/F</sup> hearts receiving low-dose AAV-Cre revealed a remarkable disruption of T tubules in mG<sup>+</sup> CMs from NAE1<sup>F/F</sup> hearts, but not in mT<sup>+</sup> CMs from NAE1<sup>F/F</sup> hearts or in mG<sup>+</sup> or mT<sup>+</sup> CMs from NAE1<sup>F/+</sup> hearts (Figure 2D). Quantification of T-tubule patterns showed a significant reduction of T-tubule integrity and regularity in mG<sup>+</sup> CMs from NAE1<sup>F/F</sup> hearts (Figures 2E and 2F). Together these data suggest that neddylation is essential for T-tubule organization.

In addition to T-tubule development, CM maturation is accompanied by CM growth and switch of fetal to adult gene expression.<sup>1</sup> We isolated CMs from low-dose AAV-treated

NAE1<sup>F/F</sup>:mTmG hearts and found that mG<sup>+</sup> CMs exhibited decreased cell area and increased length-to-width ratio compared with mT<sup>+</sup> CMs, indicating an important role for neddylation in CM growth (Figure 2G). We further assessed the expression of the fetal and adult isoforms of genes involved in sarcomere and electrophysiological maturation. Quantitative real-time PCR analysis of medium-dose AAV-treated hearts revealed a significant downregulation of sarcomeric adult isoforms, including *Myh6, Tnni3,* and *Myl2,* and potassium channel gene *Kcnj2* in NAE1<sup>F/F</sup> hearts compared with NAE1<sup>F/+</sup> hearts. In contrast, the fetal isoforms of these genes, such as *Myh7, Tnni1, Myl7,* and *Hcn4,* were drastically upregulated (Figure 2H). Immunoblotting confirmed these changes at the protein level in medium-dose AAV-treated hearts (Figures 2I and 2J). Thus, these data identify an essential role for neddylation in CM maturation.

## Transcriptome analysis reveals defective maturation and metabolic dysregulation in NAE1deficient hearts

To gain insights into how neddylation regulates CM maturation, we sought to conduct transcriptional profiling. Analysis of mouse hearts with AAV-Cre-mediated mosaic NAE1 deletion may underestimate the transcriptional changes, and isolation and sorting of viable adult mG<sup>+</sup> and mT<sup>+</sup> CMs from NAE1<sup>F/F</sup> hearts is challenging. Therefore, we chose to analyze the transcriptomes of aMHC<sup>Cre</sup>-driven neonatal NAE1 knockout hearts (NAE1<sup>CKO</sup>) (Figure 3A). Principal-component analysis revealed patterns distinguished between NAE1<sup>CKO</sup> and littermate control groups (Figure 3B). Differential gene expression analysis identified 959 downregulated and 735 upregulated genes, with Nae1 being one of the top downregulated genes (Figure 3C, Table S1). Consistent with the findings in AVV-infected hearts, the ratios of fetal to mature myosin heavy chain isoforms (Myh7 to Myh6) and troponin I isoforms (Tnni1 to Tnni3) were also significantly increased in NAE1<sup>CKO</sup> hearts (Figure 3D). To further analyze the global impact of NAE1 deletion on the CM maturation status, gene set enrichment analysis (GSEA) was performed to assess the enrichment of differentially expressed genes among the previously identified mature (293 genes) and immature (354 genes) gene sets common in human and mouse.<sup>45</sup> Genes upregulated in NAE1-deficient hearts were highly enriched for immature genes (normalized enrichment score [NES] = -2.32; Figure 3E), while downregulated genes were highly enriched for mature genes (NES = 3.38; Figure 3F). GSEA of the differentially expressed genes among the top 100 neonatal- or adult-specific genes identified in mouse heart<sup>3</sup> also revealed a similar trend: upregulated genes were enriched for neonatal genes (NES = -1.04; Figures S3A and S3C), while downregulated genes were enriched for adult genes (NES = 1.31; Figures S3B and S3D). These data suggest that inhibition of neddylation results in persistent expression of genes associated with immaturity and inactivation of the transcriptional network required for CM maturation.

We next analyzed the RNA-sequencing (RNA-seq) data to identify biological processes enriched within the differentially expressed genes in NAE1-deficient hearts. Interestingly, the downregulated genes were highly enriched for oxidative phosphorylation and fatty acid metabolism, while the upregulated genes were enriched for more diverse cellular processes, including hypoxia signaling and glycolysis (Figure 3G). Specifically, many genes involved in fatty acid oxidation, mitochondrial fatty oxidative oxidation, and electron transportation

chain were significantly downregulated in NAE1-deficient hearts (Figures 3H and S3E), whereas genes involved in glucose transport and glycolysis were either up- or downregulated (Figure S3F). Interestingly, many of these dysregulated metabolic genes were enriched in PPARa and HIF1a signaling (Figure 3I), suggesting their potential involvement in metabolic dysregulation. Screening of a list of key metabolic transcriptional regulators showed a significant downregulation of PERM1 and PPARa, but not others, such as HIF1a, in NAE1-deficient hearts (Figure S3G). These data identify a link between neddylation and cardiac metabolic maturation.

#### Defective oxidative metabolism in NAE1-deficient hearts

Perinatal metabolic transition from glycolysis to oxidative metabolism is essential for CM maturation and postnatal cardiac development.<sup>8,46</sup> Quantitative real-time PCR analysis showed that several genes involved in fatty acid utilization, such as Dgat2, Hadha, Mlycd, and Eci1, were significantly downregulated in medium-dose AAV-Cre-infected NAE1F/F hearts compared with NAE1<sup>F/+</sup> hearts, whereas *Igf1*, a gene that stimulates glucose utilization, was markedly upregulated (Figure 4A). In contrast, we did not observe a significant change in stress markers (Nppa, Nppb, and Myh6) (Figure S4A), consistent with the lack of pronounced cardiac dysfunction in these hearts (Figure S1C). Moreover, western blotting revealed a decrease in the enzyme regulating fatty acid utilization (acyl-CoA synthetase long chain family member 1, ACSL1) and proteins involved in mitochondrial biogenesis (PGC1a and PERM1)<sup>47</sup> in medium-dose AAV-Cre-infected NAE1<sup>F/F</sup> hearts (Figure 4B and 4C). Measurement of respiration function of isolated cardiac mitochondria showed a substantial reduction in basal and maximal mitochondrial respiration in NAE1<sup>F/F</sup> hearts (Figures 4D and 4E). In addition, the ATP content in NAE1<sup>F/F</sup> hearts also decreased to nearly half of the levels in NAE1<sup>F/+</sup> hearts (Figure 4F). Since medium-dose AAV-Cre deletes NAE1 in ~60% of CMs, these metabolic changes may be underestimated, highlighting the impact of neddylation on cardiac metabolism.

Cardiac metabolism switching from glycolysis to oxidative metabolism starts at midgestation.<sup>6</sup> We sought to determine whether NAE1<sup>CKO</sup> affects cardiac metabolic function. Quantitative real-time PCR analysis showed that NAE1<sup>CKO</sup> led to dramatically decreased mRNA levels of fatty acid oxidation genes, including *Acadm, Cpt1b*, and *Atg1* (Figure 4G). Ultra-structural analysis revealed a significant increase in lipid droplets in mutant CMs (Figures S4B and S4C). Oil red O (ORO) staining revealed increased accumulation of lipid droplets in NAE<sup>CKO</sup> hearts compared with littermate control hearts (Figure S4D). Meanwhile, NAE1-deficient CMs also displayed a remarkable increase in degenerating/immature mitochondria with loose and fragmented cristae and mitophagic vesicles (Figures 4H and 4I), suggesting mitochondrial dysfunction. Thus, the *in vivo* findings from NAE1-deficient hearts support a critical role for neddylation in instigating cardiac oxidative metabolism.

#### Inhibition of neddylation impairs fatty acid utilization in cultured CMs

To study whether neddylation regulates fatty acid utilization in a cell-autonomous manner, neonatal rat ventricular CMs (NRVCs) were treated with MLN4924 (MLN), a potent and specific NAE1 inhibitor with minimal effect on Ub or other Ub-like proteins,<sup>48</sup> or

transfected with siRNAs against both subunits (NAE1 and UBA3) of NAE to inhibit neddylation (Figures 5A and S5A). Since cultured CMs are prone to using glucose as a major energy source, NRVCs were treated with oleic acid (OA) to boost fatty acid utilization. Silencing of NAE and MLN treatment led to greater accumulation of lipid as measured by LipidTOX and BODIPY labeling and quantification of triglyceride contents (Figures 5C, 5D, and S5C–S5F). Mitochondrial stress test revealed that both treatments significantly impaired mitochondrial bioenergetics and resulted in significantly diminished basal and maximal respiration (Figures 5E and 5F). Palmitate oxidation stress test further revealed that silencing of NAE suppressed fatty acid utilization (Figures 5G and 5H). MLN treatment significantly blunted OA-induced upregulation of genes crucial for fatty acid utilization, such as Cpt1b and Atgl, and mitochondrial biogenesis, such as Pgc1a and Pgc1b, and attenuated OA-induced downregulation of the glycolytic gene *Pkm*, although it had little effect on *Pparg* and *Hk2* expression (Figure 5I). MLN also significantly decreased the expression of PGC1a (a master regulator of mitochondrial biogenesis), CPT1B (carnitine palmitoyltransferase 1B; the rate-controlling enzyme of long-chain fatty acid β-oxidation), and ACSL1 (acvl-CoA synthetase long-chain family member 1; an isozyme of the longchain fatty acid-coenzyme A ligase) (Figures S5A and S5B). Together, these data suggest that inhibition of neddylation represses fatty acid oxidative metabolism in CMs.

#### Metabolomics analysis revealed altered metabolic intermediates in MLN-treated NRVCs

To understand the broader impact of neddylation on CM metabolism, we performed untargeted metabolomics analysis of cultured CMs with and without MLN treatment. Principal-component analysis (PCA) of the detected metabolites clearly distinguished between vehicle (Veh)- and MLN-treated cells (Figure S6A). Among 1,436 annotated metabolites (Table S2), 205 were significantly downregulated, while 208 were upregulated, in MLN-treated CMs (fold change [FC] > 1.5, adjusted p < 0.05; Figure S6B). Integrated pathway enrichment analysis of the significantly altered metabolites identified many metabolic pathways significantly affected by neddylation inhibition (Figure S6C and Table S2). Pathways with top enrichment included critical cellular glucose and fatty acid metabolism, such as fatty acid biosynthesis, carnitine synthesis, Warburg effect, and glycolysis, as well as multiple interconnected amino acid metabolic pathways. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of these metabolites also identified similar enriched pathways (Figure S6D). Individual metabolites whose levels were altered by treatment with MLN are shown in Figure S6E. Taken together, the results of the metabolomics analysis suggest that inhibition of neddylation has a global impact on the metabolic profile, especially in the pathways related to glucose and fatty acid metabolism in CMs.

#### Persisting HIF1a signaling in neddylation-deficient CMs

Activation of HIF1a promotes glycolysis, suppresses fatty acid oxidation, and inhibits mitochondrial biogenesis and oxidative phosphorylation.<sup>49–51</sup> Developmental downregulation of HIF1a in the heart is essential for perinatal metabolic transition and cardiac chamber development.<sup>6</sup> The enrichment of dysregulated genes in HIF1a signaling (Figure 3I) prompted us to explore a possible link between neddylation and HIF1a signaling. Analysis of chromatin immunoprecipitation sequencing (ChIP-seq) data of HIF1a

in embryonic day 12.5 mouse hearts<sup>21</sup> showed that 155 (9.1%) of the dysregulated genes in NAE1-deficient hearts were putative HIF1a targets (Figure 6A). Gene ontology (GO) enrichment analysis demonstrated that these 155 genes were mostly associated with fructose and pyruvate metabolism and mitochondria, as well as cardiac muscle contraction and morphogenesis (Figure 6A). Specifically, many HIF1a-regulated glycolytic, fatty acid oxidative, and mitochondrial genes were downregulated in NAE1-deficient hearts (Figure 6B). We confirmed that deletion of NAE1 caused a substantial accumulation of HIF1a proteins without altering its transcripts (Figures 6C and 7D). Consistent with previous reports,<sup>6,21</sup> HIF1a was abundant in E9.5 mouse hearts but remarkably downregulated in E14.5 mouse hearts and mainly resided in the cytosol of CMs (Figures S7A and 6E). However, HIF1a accumulated in the nucleus of NAE1-deficient CMs at E14.5 (Figures 6E and 6F), a time point when cardiac morphology was comparable between control and mutant hearts.<sup>41</sup> Moreover, Glut1, a glucose transporter that is a known HIF1a downstream target, was upregulated in mG<sup>+</sup> (NAE1-deleted) CMs, but not in mT<sup>+</sup> CMs, in E14.5 mouse hearts (Figures 7G and 7H), supporting the activation of HIF1a. Similarly, depletion of NAE1 via AAV-Cre also led to accumulation of HIF1a in postnatal hearts (Figures 6I and 6J) and downregulation of HIF1a target genes involved in fatty acid metabolism (Dgat2, Acaa2) and mitochondrial function (*Ech1, Slc25a33, Coq9*) (Figure 6K). HIF1a reporter assay showed that both silencing of NAE and MLN treatment increased HIF1a activity in H9C2 and HEK293 cells (Figures S7B–S7D). Taken together, these results suggest that inhibition of neddylation promotes accumulation and activation of HIF1a, which in turn represses the establishment of oxidative metabolism in the developing heart.

#### Neddylation regulates HIF1a expression in Cul2-dependent and -independent manners

HIF1a expression is largely controlled at the posttranscriptional level. Under normoxic conditions, HIF1a is ubiquitinated by Cul2-von Hippel-Lindau (VHL) ubiquitin ligase and subsequently degraded by the proteasome.<sup>52</sup> Neddylation is essential for cullin-RING ubiquitin ligase activity,<sup>53</sup> and inhibition of neddylation via MLN or NAE1<sup>CKO</sup> robustly increased HIF1a in CMs (Figures 6D, 6I, 7A, and S7E). Interestingly, however, MLN and bortezomib (BZM; a 20S proteasome inhibitor) had synergistic effects in stabilizing HIF1a in CMs under both normoxic and hypoxic conditions (Figure 7A), suggesting that neddylation functions independent of Cul2 to control HIF1a expression. Immunoprecipitation of HIF1a under denatured conditions, which prevents non-covalent protein-protein interactions, identified neddylated species, which were absent in cells expressing conjugation-deficient NEDD8 mutant and reduced by MLN treatment (Figure 7B). Moreover, overexpression of NEDD8 E2 enzyme UBC12 also increased neddylated HIF1a (Figure 7C), further supporting HIF1a as a putative NEDD8 target. Furthermore, MLN remained effective in stabilizing HIF1a in Cul2-deficient CMs (Figures 7D and 7E). These data suggest that neddylation of HIF1 $\alpha$  promotes its degradation in a manner that is independent of Cul2 ubiquitin ligase. Inhibition of HIF1a with echinomycin (Ech), a compound that inhibits HIF1a binding to DNA and thus its transcriptional activity,<sup>54</sup> substantially reduced MLN-induced lipid accumulation in CMs (Figure 7F), and this was further confirmed by quantification of triglyceride (TG) content (Figure 7G). Thus, we propose that neddylation has dual roles in the regulation of HIF1a expression and that upregulation of HIF1a affects fatty acid utilization in neddylation-deficient CMs.

#### DISCUSSION

In this study, we demonstrated that neddylation is required for CM maturation and perinatal cardiac development by ensuring developmental metabolic transition. Our findings support a model in which neddylation modifies HIF1a and Cul2, and neddylation of both proteins has a synergistic effect in promoting efficient HIF1a ubiquitination and degradation, which is essential for the establishment of oxidative metabolism in the developing heart (Figure 7H). Consequently, inhibition of neddylation leads to accumulation of HIF1a proteins and persistent HIF1a signaling, which represses fatty acid utilization in late gestational and postnatal heart, leading to defects in CM maturation and eventually heart failure. Thus, our study identifies neddylation as a crucial posttranslational mechanism regulating cardiac maturation and metabolism.

The biological functions of neddylation have been primarily described in the context of its impact on cell differentiation and proliferation,<sup>31–35</sup> but its significance in terminally differentiated, postmitotic organs has not been investigated. Using AAV-TnT-Cre to achieve mosaic, postnatal gene deletion in the heart, our study defines a role for neddylation in CM maturation. This is evidenced by a disrupted T-tubule network, decreased CM cell size, and significantly dysregulated expression of maturation genes in neddylation-deficient CMs in the absence of overt cardiac dysfunction (Figures 2 and 3). Consistent with an arrest in cardiac maturation, mice with high-level deficiency of neddylation developed cardiomyopathy and heart failure before adolescence (Figure 1), and genetic deletion of NAE1 in embryonic heart at midgestational stage via aMHC<sup>Cre</sup> induces heart failure and perinatal lethality.<sup>41</sup> Notably, deletion of CSN8, a subunit of the deneddylase COP9 signalosome (CSN), in postnatal hearts via aMHC<sup>Cre</sup> causes dilated cardiomyopathy and heart failure by 3 weeks of age.<sup>38</sup> Transient inhibition of neddylation with MLN4924 during the first week after birth predisposes the heart to isoproterenol-induced pathological remodeling.55 Since perturbations of deneddylation or neddylation in these studies occurred in the critical time window of CM maturation, disruption of CM maturation may contribute to the observed cardiac phenotypes. ASB2, a Cul5-RING Ub ligase whose activity is regulated by neddylation, was shown to regulate CM maturation by facilitating sarcomere organization and formation of cell-cell junctions.<sup>56</sup> Together, recent findings from our studies and others support a previously unrecognized mechanism regulating CM maturation and perinatal cardiac development.

Increasing evidence has suggested a critical role for a metabolic shift from glycolysis to oxidative metabolism in CM maturation. Perturbations of PGC1/PPAR signaling, an important pathway regulating mitochondrial biogenesis and maturation, disrupts CM maturation, whereas PGC1/PPAR activation improves the maturation of pluripotent stem cell-derived CMs.<sup>5</sup> Similarly, disruption of ERR $\alpha$  and ERR $\gamma$ , which function as critical transcriptional activators of metabolic genes in adult CM, impairs cardiac maturation and results in heart failure in the developing heart.<sup>19</sup> Findings from this study establish neddylation as a crucial mechanism in the regulation of cardiac oxidative metabolism. We present *in vitro* and *in vivo* evidence showing that inhibition of neddylation disrupts the expression of metabolic genes, inhibits mitochondrial maturation and respiration, suppresses fatty acid utilization, and significantly alters metabolite profiles in CMs (Figures 3, 4,

5, and S3–S6), which collectively culminate in the arrest of CM maturation. Consistent with our results, inhibition of neddylation via deletion of NEDD8 or UBA3 in the liver suppressed mitochondrial oxidative phosphorylation and fatty acid oxidation, leading to hepatic steatosis.<sup>33</sup> Interestingly, MLN4924 treatment and UBA3 knockdown were shown to enhance basal and maximal oxidative phosphorylation in cancer cell lines,<sup>57</sup> suggesting that the effect of neddylation in metabolism could be cell-type dependent.

The spatiotemporal downregulation of HIF1a in the developing heart is crucial for the metabolic transition from glycolysis to oxidative metabolism and cardiac maturation. Despite its essential role in stimulating CM proliferation in hypoxic embryonic hearts,<sup>21</sup> persistent HIF1a activation in postnatal hearts has been linked to heart failure and premature death, at least in part due to defective energy metabolism.<sup>17,58–61</sup> Deletion of the E3 ubiquitin ligase VHL in the developing heart results in HIF1a hyperactivation, abrogating the developmental metabolic shift and impairing cardiac maturation and function, which can be rescued by concomitant deletion of HIF1a.<sup>6</sup> Moreover, chronic perinatal hypoxia is sufficient to delay cardiac maturation.<sup>62</sup> We observed accumulation of HIF1a (Figures 6 and 7) and deficits in oxidative metabolism (Figures 4 and 5) in neddylation-deficient hearts and cultured CMs, and inhibition of HIF1a attenuated lipid accumulation in neddylation-deficient CMs (Figure 7G). Thus, our data suggest that neddylation regulates developmental metabolic reprogramming, at least in part, by repressing HIF1a signaling the heart.

Identification of NEDD8 substrates is of utmost importance to elucidate the biological functions of neddylation. Consistent with the findings in non-cardiac cells,<sup>63–66</sup> we confirmed that HIF1a is degraded by Cul2-VHL Ub ligase and is also a putative NEDD8 target in CMs (Figure 7). Interestingly, inhibition of neddylation in the absence of Cul2 remains effective in stabilizing HIF1a, suggesting that neddylation of HIF1a promotes its degradation. Thus, neddylation appears to regulate HIF1a by directly targeting Cul2 and HIF1a, respectively. While neddylation itself does not directly target the modified substrates for proteasomal degradation under basal conditions, it is reported that NEDD8 incorporates into the existing Ub chain under stress conditions to facilitate the degradation of ubiquitinated proteins,<sup>67,68</sup> which may otherwise prevent the exhaustion of the ubiquitin machinery. Further experiments are needed to identify the neddylation site on HIF1a and elucidate the biological functions of HIF1a neddylation.

As a protein modification that targets diverse cellular proteins,<sup>69,70</sup> neddylation may have multiple downstream effectors that coordinate CM metabolism. Other than HIF1a, mitochondrial electron transfer flavoproteins A and B (ETFA and ETFB), two key proteins responsible for relaying electrons in the electron transport chain, were identified as neddylated substrates, and neddylation increased the stability of ETFA and ETFB by preventing their ubiquitination and degradation in hepatocytes.<sup>33</sup> PPAR $\gamma$  neddylation was reported to control the expression of genes involved in fatty acid storage and is essential for adipogenesis.<sup>32</sup> Whether neddylation of these proteins regulates cardiac developmental metabolic reprogramming remains to be determined. It should be pointed out that the NEDD8 proteome is likely cell-type specific. Mapping the NEDD8 proteome landscape will provide mechanistic insights into how neddylation regulates cardiac homeostasis.

#### Limitations of the study

There are still some limitations in this study. First, we cannot exclude the possibility that neddylation inhibition perturbs the Hippo-YAP pathway, as we reported previously,<sup>41</sup> which may have effects on CM metabolism<sup>71</sup> and the last round of proliferation and division.<sup>72</sup> Second, single-cell or single-nucleus RNA-seq of cells isolated from hearts infected with medium- or low-dose AAV-Cre will provide precise transcriptomic changes in neddylation-deficient CMs, which may define the metabolic phenotype independent of ongoing cardiac remodeling. Third, neddylation may have a direct impact on multiple pivotal cellular processes beyond cardiac metabolism and maturation, such as CM contractility, T-tubule remodeling, and Ca<sup>2+</sup> handling. Defects in these pathways may contribute to the cardiac phenotype observed in NAE1-deficient hearts.

## **STAR**\*METHODS

#### **RESOURCE AVAILABILITY**

**Lead contact**—Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Huabo Su (hsu@augusta.edu).

**Materials availability**—All reagents generated in this study will be made available on request from the lead contact with a completed Materials Transfer Agreement.

#### Data and code availability

- All sequencing data have been deposited at GEO and are publicly available as of the date of publication. The accession number is listed in the key resources table (GEO: GSE217964). All microscopy data in this paper will be available upon request to the lead contact.
- No specific code was used in this article.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

#### EXPERIMENTAL MODEL AND SUBJECT DETAILS

**Animals**—All animal experiments were approved by the Augusta University Institutional Animal Care and Use Committee. A transgenic mouse line bearing a NAE1<sup>Flox</sup> allele was crossed with aMHC<sup>Cre</sup> mice (the Jackson Laboratory, strain # 011038) to generate CM-restricted NAE1 knockout (NAE1<sup>CKO</sup>) mice. A transgenic mouse line bearing the Rosa26<sup>mTmG</sup> allele (the Jackson Laboratory, strain # 007676) was used for lineage tracing. These mice were maintained in the C57BL/6J inbred background for our studies.

During all experiments involving transgenic mice, experimental mice were randomly assigned into all groups, including sex (male and female), age (8–12 weeks for breeding/4, 6 weeks or neonatal P1 as specified in each figure), unless specified. The total estimate number of mice used in this article is ~180 mice (including embryonic stage mice) and ~120 rat pups for NRVC isolation. All mice were at healthy status before experiments. No subjects were involved in previous procedures except for AAV injections indicated

in specific figures at age of P1. The housing conditions were well maintained at room temperature in the animal facility of Augusta University. The influence of sex was not determined for 4 or 6 weeks sacrificed mice. The influence of sex of P1 pups was considered as not significant.

**Ethical statement**—Our studies did not include human participants, human data, or human tissue. All animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at Augusta University.

**Culture of neonatal cardiomyocytes and cell lines**—Neonatal rat ventricular cardiomyocytes (NRVCs) were isolated using Neonatal Cardiomyocyte Isolation System (Worthington) following the manufacturer's protocol.<sup>40</sup> Briefly, neonatal rat hearts were minced into ~1 mm diameter and digested in 0.05% Trypsin in 4°C overnight on a slow speed rocker. The other day, digested heart tissue was washed 4 times and subject to Collagenase digestion at 37°C for 40 min. NRVCs were next separated by pipet flushing and through 70 mm filter, pre-plated for 2 h to exclude cardiac fibroblast, and finally plated in 60-mm dishes in DMEM containing 10% FBS, 1% P/S and 1x BrdU for two days. The culture media was next changed to 2% FBS, which could be cultured in 37°C incubator with 5% CO<sub>2</sub> for at most 3 days prior to use. Hypoxia condition was created by N<sub>2</sub> humidified chamber with 5% CO<sub>2</sub> and 1% O<sub>2</sub> supplied at 37°C for 24 h.

HEK293 cells were cultured in DMEM supplemented with 10% fetal bovine serum at 37°Cand 5% CO<sub>2</sub>. pShuttle-CMV-SF-NEDD8 (Strep- and FLAG-tagged NEDD8) was generated as described.<sup>40</sup> The plasmids were transfected into the cells using X-tremeGene HP DNA transfection reagent (Roche) according to the manufacturer's protocol. Cells were harvested for analysis 48-72 h after transfection or as indicated.

Some of the cells were treated with vehicle (DMSO or BSA), 1  $\mu$ M MLN4924 (Active Biochem), 100 nM bortezomib (Enzolife), or 1 nM Echinomycin (Thermo Fisher) where applicable.

#### METHOD DETAILS

Adeno-associated virus infection—AAV9 virus expressing Cre under the control of a mouse cardiac troponin T promoter (AAV9-cTnT-Cre)<sup>42</sup> (Vigene Biosciences) was subcutaneously injected into mice at age P1 at the indicated doses (high dose:  $5 \times 10^{11}$  GC/pup; medium dose:  $0.5 \times 10^{11}$  GC/pup; low dose:  $0.25 \times 10^{11}$  GC/pup). Genotyping of mouse pups were blind to injection performer.

*In situ* t-tubule labeling, imaging, and quantification—The hearts from AAVinfected mice were isolated and perfused with FM4-64FX and subjected to *in situ* confocal microscopy. The t-tubule content, integrity and regularity were next analyzed in ImageJ following previously described STAR Methods.<sup>79</sup> Briefly, intact mouse hearts were Langendorff-perfused at room temperature with Tyrode's solution (NaCl 137, KCl 5.4, HEPES 10, Glucose 10, MgCl<sub>2</sub> 1, NaH<sub>2</sub>PO<sub>4</sub> 0.33, pH adjusted to 7.4 with NaOH, oxygenated with 95% O<sub>2</sub> and 5% CO<sub>2</sub> during experiments), containing 10  $\mu$ M FM4-64FX, a lipophilic fluorescence indicator of membrane structure (Thermo Fisher), for 20 min. The

membrane structure of epicardial myocytes was analyzed *in situ* with confocal microscope (STELLARIS 8, Leica Microsystems). T-tubule images were next analyzed with IDL image analysis program (ITT VIS Inc., Colorado). Background noise in confocal images was filtered with a threshold value retrieved from image intensity histogram. T-tubule two-dimensional images were converted to frequency domain using the Fast Fourier Transformation function in IDL, so that it could be determined whether repeating patterns occur (T-tubule regularity) and how strong the repeating patterns are (T-tubule power).

**RNA-seq analysis**—Mouse ventricles were minced and treated with RNAlater (Thermo Fisher) according to the manufacturer's protocol at  $-80^{\circ}$ C. The isolated RNA was subjected to RNA-sequencing analysis performed by Genome Technology Access Center (GTAC) at Washington University via Next Generation Sequencing. Genotyping information of the mice was pre-coded and blind during RNA-seq analysis and data analysis.

**Lipid droplets staining assays**—Cells were stained with LipidTOX kit or BODIPY staining following the manufacturer's protocol (Thermo Fisher #H34475 or #D3922, respectively). Briefly, after indicated treatment, NRVCs grown on coverslips were fixed in 4% paraformaldehyde at room temperature for 10 min and subjected to LipidTOX labeling (1: 1000 in PBS, RT for 30 min) or BODIPY labeling (1: 5000 in PBS, RT for 30 min). The cells were counterstained with cardiac Troponin-T (TnT)/Phalloidin (Thermo Fisher) and DAPI (diamidino-2-phenylindole, Thermo Fisher) to label cardiomyocytes and nuclei, respectively. Confocal images were quantified by ImageJ. LipidTOX/BODIPY intensity was normalized with DAPI intensity. Eight views/sample, 3 samples/group were quantified.

**Triglyceride (TG) measurement**—Cells were lysed in 1% Triton X-100 in PBS. The concentrations of TG were measured using a TG assay kit (Infinity Triglycerides kit) following the manufacturer's protocol. The colormetric readings were collected with a microplate reader at OD 570 nm and the data were normalized to total proteins.

**Metabolomics analysis**—Cell pellets (~2.4X10<sup>7</sup> cells/biological replicate) were collected and snap frozen in liquid nitrogen for untargeted metabolomics analysis (Creative Proteomics, NY). A total of 4 control samples and 4 MLN-treated samples were included in this analysis. No sample was excluded since sample submission. Briefly, samples were thawed in 800 µL of 80% methanol, sonicated at 4°C for 30 min, kept at -40°C for 1 h, vortexed for 30 s, and centrifuged at 12000 rpm at 4°C for 15 min. Finally, 200 µL of supernatant and 5 µL of DL-o-chlorophenylalanine (140 µg/mL) were used for LC-MS analysis. Quality control (QC) samples were prepared using the same sample preparation procedure. Samples were separated by Ultimate 3000LC combined with Q Exactive MS (Thermo) and screened with ESI-MS. The LC system is comprised of an ACQUITY UPLC HSS T3 ( $100 \times 2.1 \text{ mm} \times 1.8 \mu\text{m}$ ) with Ultimate 3000LC. The mobile phase was composed of solvent A (0.05% formic acid water) and solvent B (acetonitrile) with a gradient elution. The flow rate of the mobile phase was 0.3 mL/min. The column temperature was maintained at  $40^{\circ}$ C, and the sample manager temperature was set at  $4^{\circ}$ C. Mass spectrometry parameters in ESI- mode are as follows: heater temperature 300°C, sheath gas flow rate, 45 arb; auxiliary gas flow rate, 15arb; sweep gas flow rate, 1 arb; spray voltage, 3.2 kV; capillary

temperature,350°C; S-Lens radiofrequency level, 60%. Sample information of specific treatments was blind during metabolomics analysis and data collection.

The raw data were acquired and aligned using MetaboAnalyst  $5.0^{79}$  based on the m/z value and the retention time of the ion signals. Principal component analysis, statistical analysis, enrichment analysis, pathway analysis and networking analysis were also performed under the MetaboAnalyst 5.0 platform. A value of p < 0.05 was considered statistically significant unless specifically defined.

**Embryo isolation**—Female mice crossed with their mating partners were checked for plug formation. Mouse embryos at different embryonic ages were dissected and washed in cold PBS. Embryo heads and lower dorsal parts were removed prior to fixation. For immunostaining, the embryos were fixed in cold 4% paraformaldehyde overnight at  $4^{\circ}$ C, 70% ethanol overnight at  $4^{\circ}$ C, and subjected to either OCT embedding for cryosection or paraffin processing and embedding for paraffin sections at thickness of 5 µm. Approximately 60 embryos within 8 litters were used in this article. The grouping was determined by the genotyping of yolk sac of individual embryo. Sex was not considered at this stage of embryonic development.

**Echocardiography**—Perinatal mice were anesthetized by inhalation of isoflurane (2.5% for induction and 1.5% for maintenance) via a nose cone. The adequacy of anesthesia was monitored by toe pinch. Cardiac images and loops were recorded using a VEVO 2100 echocardiography system with a 30MHz transducer (Visual Sonics). The LV morphometric and functional parameters were analyzed offline using VEVO 2100 software. Echocardiography of conscious neonates was performed by gently securing the mice on the station with tapes. Mice information including genotyping and treatment was blind to echocardiography performer.

**Histology and immunohistochemistry analysis**—For histology analysis, 5-µm OCT-embedded cryosections were subjected to Fast Green/Sirius Red staining. For immunohistochemistry analysis, cryosections were subjected to antigen retrieval in preheated sodium citrate buffer (pH 6.0, 98°C) for 10 min with the PT Link system (Dako). For cryo-sectioned tissues, deparaffinizing and antigen retrieval procedure were replaced by treatment of 1% Triton X-100 in PBS for 10 min at room temperature. After pre-incubation with 10% non-immune goat serum (Thermo Fisher Scientific) to prevent non-specific binding, tissue sections were incubated with primary antibodies at 4°C overnight and subsequently with appropriate Alexa-Fluor conjugated secondary antibodies (Thermo Fisher Scientific) for 1 h at room temperature. Finally, sections were stained with DAPI (Sigma) and mounted in VECTASHIELD antifade mounting medium (Vector Laboratories). Images were captured with Olympus BX41 (Olympus) or Zeiss Upright 780 confocal microscope (Zeiss). Section information was pre-coded and blind to procedure performers including embedding, sectioning, staining and imaging.

**Protein extraction and Western blot analysis**—Protein was extracted from ventricular myocardium tissues or cultured cells, concentration determined with BCA reagents (Thermo Fisher Scientific), and SDS-PAGE, immunoblotting, and densitometry

analysis were performed as previously described.<sup>38</sup> Briefly, frozen tissue or cell was homogenized in lysis buffer (50 mm Tris-HCl pH 6.8 containing 1% SDS, 10% glycerol, and complete protease inhibitor mixture), sonicated and spin down at 14,000 rpm. The supernatant was collected and boiled for 10 min. After protein concentration was determined, the protein lysate was mixed with half the volume of 3x SDS loading buffer with 15%  $\beta$ -mercaptoethanol. The mixed sample was next boiled for 5 min and subjected to SDS-PAGE gel isolation, transferred to PVDF membrane, and blotted with specific primary antibody followed by secondary antibody conjugated with HRP and film development. No unique technique of Western blot was conducted. Primary antibodies used in this study are listed in key resources table and detailed in Table S3.

All uncropped WB figures can be found in Supplemental Materials.

**Immunoprecipitation**—For denaturing IP, cells were lysed in TSD buffer (50 mM Tris pH 7.5, 1% SDS, 5 mM DTT) containing a cocktail of phosphatase and protease inhibitors (Sigma). The lysates were then diluted with 10-fold volume of TNN buffer (50 mM Tris pH 7.5, 250 mM NaCl, 5 mM EDTA, 0.5% NP-40), and incubated with primary antibody and protein A Sepharose beads (ThermoFisher Scientific) with rotation at 4°C overnight. For Biotin-IP, cells were lysed by RIPA buffer (NaCl 150mM, Tris-HCl pH 7.4 10mM, EDTA 1mM, Triton X-100 1%, SDS 0.1%, Sodium deoxycholate 0.1%) and incubated with NeutrAvidin agarose resin (Thermo Scientific, #29201) with rotation at 4°C overnight. Immunoprecipitates were eluted with SDS-PAGE sampling buffer at 95°C for 5 min, and subjected to SDS-PAGE and immunoblotting.

**RNA preparation and real-time PCR**—Isolation of total RNA and reverse transcription into single-stranded cDNA was performed as previously described.<sup>41</sup> Briefly, Total RNA was isolated from heart tissue or NRVCs using the TRIzol Reagent (Invitrogen) following the manufacturer's protocol. Gene expression levels were measured in at least triplicate per sample by real-time quantitative PCR (StepOnePlus Real-Time PCR system, Thermo Fisher Scientific) using the SYBR-Green assay with gene-specific primers at a final concentration of 200 nM. Relative gene expression was calculated using the 2<sup>- ct</sup> method against a rat house-keeping gene acidic ribosomal phosphoprotein P0 (RPLP0) or a mouse house-keeping gene hypoxanthine guanine phosphoribosyl transferase 1 (Hprt) as appropriate. The primers used for qPCR are listed in Key Resources Table and detailed in Table S4.

#### siRNA transfection—siRNAs against rat Cul2 (5'

### - TTCGAGCGACCAGTAACCTTA-3') and luciferase (5'

-AACGTACGCGGAATACTTCGA-3') were used. Briefly, NRVCs were transfected with siRNAs (100 pmol per 2×10<sup>6</sup> cells) using Lipofectamine RNAimax (Thermo Fisher Scientific) following the manufacturer's protocol at 24–48 h after plating. Six hours after the transfection, the siRNA-containing medium was replaced with fresh medium containing 2% FBS. In some experiments, a second round of siRNA transfection may be performed 2 days after the first transfection to achieve sustained gene silencing.

**ATP content measurement**—Cells were lysed in cold 10% trichloroacetic acid (TCA) and diluted 100-fold in Tris-acetate (pH 7.8). ATP content was measured by ATP

Bioluminescent Assay Kit (Sigma, #FL-AA) on a luminescent microplate reader and normalized to total protein levels.

**Dual luciferase assay**—The dual luciferase assay was performed following the manufacture protocol of Dual-Luciferase Reporter Assay System (Promega). Specifically, HRE-firefly-luciferase and Renilla luciferase were co-transfected in H9C2 cells and cultured for 72 h. Next, the firefly and Renilla luciferase activities of the same sample were sequentially measured by a luminometer after addition of specific substrates, with the ratio of firefly to Renilla luciferase activity (Fluc/Rluc) as readout of HIF-1a activity.

**Plasmids**—HA-HIF1a (#18949), HRE-firefly-luciferase (#26731), Renilla luciferase (#118016), 5HRE-GFP (#46926) plasmids were obtained from Addgene. Received bacteria were amplified and correlating plasmids were extracted with Plasmid Maxi kit (Qiagen) following manufactures instructions. pShuttle-CMV-FLAG-NEDD8 and pShuttle-CMV-FLAG-NEDD8-dGG plasmids were generated as previously described.<sup>41</sup> Briefly, NEDD8 or NEDD8-dGG sequence was synthesized and cloned in pShuttle-CMV-FLAG construct. CAG X-bioNEDD8-BirAOV5-g2A-puro and CAG X -bioNEDD8-BirAOV5-g2A -UBC12 plasmids were a kind gift from James Sutherland at CIC bioGUNE.<sup>77</sup>

#### QUANTIFICATION AND STATISTICAL ANALYSIS

Results are shown as mean  $\pm$  SEM. Paired data were evaluated using a two-tailed Student's *t*-test. For multiple comparisons, one-way analysis of variance (ANOVA) or when appropriate, two-way ANOVA, followed by post hoc test was performed.

A p-value < 0.05 was considered statistically significant. In figures, different p value was labeled as follow: NS, p > 0.05; \*, 0.05 > p = 0.01; \*\*, 0.01 > p = 0.001, \*\*\*, 0.001 > p = 0.0001; \*\*\*\*, p < 0.0001. Specific statistical analysis method and n number of individual experiment can be found in related figure legend. All centers of bar graph in this article represent mean value of that group. All error bars in this article represent ±SEM unless stated otherwise in figure legends.

#### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

#### ACKNOWLEDGMENTS

This study was in part supported by US National Institutes of Health grants (R01HL124248 and R01HL165205 to H.S. and R01HL146807A1 to J.L.) and American Heart Association grants (19TPA34880050 to H.S., 17POST 33410592 and 19CDA34760311 to J.Z., and 16SDG30940002 to J.L.).

## INCLUSION AND DIVERSITY

One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in their field of research or within their geographical location. We worked to ensure sex balance in the selection of non-human subjects. We avoided "helicopter science" practices by including the participating local contributors from the region where we

conducted the research as authors on the paper. We support inclusive, diverse, and equitable conduct of research.

## REFERENCES

- Guo Y, and Pu WT (2020). Cardiomyocyte maturation: new phase in development. Circ. Res 126, 1086–1106. 10.1161/CIRCRESAHA.119.315862. [PubMed: 32271675]
- Padula SL, Velayutham N, and Yutzey KE (2021). Transcriptional regulation of postnatal cardiomyocyte maturation and regeneration. Int. J. Mol. Sci 22, 3288. 10.3390/ijms22063288. [PubMed: 33807107]
- VanDusen NJ, Lee JY, Gu W, Butler CE, Sethi I, Zheng Y, King JS, Zhou P, Suo S, Guo Y, et al. (2021). Massively parallel in vivo CRISPR screening identifies RNF20/40 as epigenetic regulators of cardiomyocyte maturation. Nat. Commun 12, 4442. 10.1038/s41467021-24743-z. [PubMed: 34290256]
- 4. Guo Y, Cao Y, Jardin BD, Sethi I, Ma Q, Moghadaszadeh B, Troiano EC, Mazumdar N, Trembley MA, Small EM, et al. (2021). Sarcomeres regulate murine cardiomyocyte maturation through MRTF-SRF signaling. Proc. Natl. Acad. Sci. USA 118, e2008861118. 10.1073/pnas.2008861118. [PubMed: 33361330]
- 5. Murphy SA, Miyamoto M, Kervadec A, Kannan S, Tampakakis E, Kambhampati S, Lin BL, Paek S, Andersen P, Lee DI, et al. (2021). PGC1/PPAR drive cardiomyocyte maturation at single cell level via YAP1 and SF3B2. Nat. Commun 12, 1648. 10.1038/s41467-02121957-z. [PubMed: 33712605]
- Menendez-Montes I, Escobar B, Palacios B, Gómez MJ, Izquierdo-Garcia JL, Flores L, Jiménez-Borreguero LJ, Aragones J, Ruiz-Cabello J, Torres M, and Martin-Puig S (2016). Myocardial VHL-HIF signaling controls an embryonic metabolic switch essential for cardiac maturation. Dev. Cell 39, 724–739. 10.1016/j.devcel.2016.11.012. [PubMed: 27997827]
- Karbassi E, Fenix A, Marchiano S, Muraoka N, Nakamura K, Yang X, and Murry CE (2020). Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine. Nat. Rev. Cardiol 17, 341–359. 10.1038/s41569-019-0331-x. [PubMed: 32015528]
- Lopaschuk GD, and Jaswal JS (2010). Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation. J. Cardiovasc. Pharmacol 56, 130–140. 10.1097/FJC.0b013e3181e74a14. [PubMed: 20505524]
- Schaper J, Meiser E, and Stämmler G (1985). Ultrastructural morphometric analysis of myocardium from dogs, rats, hamsters, mice, and from human hearts. Circ. Res 56, 377–391. 10.1161/01.res.56.3.377. [PubMed: 3882260]
- Dai DF, Danoviz ME, Wiczer B, Laflamme MA, and Tian R (2017). Mitochondrial maturation in human pluripotent stem cell derived cardiomyocytes. Stem Cells Int. 2017, 5153625. 10.1155/2017/5153625. [PubMed: 28421116]
- Sim CB, Ziemann M, Kaspi A, Harikrishnan KN, Ooi J, Khurana I, Chang L, Hudson JE, El-Osta A, and Porrello ER (2015). Dynamic changes in the cardiac methylome during postnatal development. FASEB J 29, 1329–1343. 10.1096/fj.14-264093. [PubMed: 25491312]
- Uosaki H, Cahan P, Lee DI, Wang S, Miyamoto M, Fernandez L, Kass DA, and Kwon C (2015). Transcriptional landscape of cardiomyocyte maturation. Cell Rep. 13, 1705–1716. 10.1016/j.celrep.2015.10.032. [PubMed: 26586429]
- Wei Y, Peng S, Wu M, Sachidanandam R, Tu Z, Zhang S, Falce C, Sobie EA, Lebeche D, and Zhao Y (2014). Multifaceted roles of miR-1s in repressing the fetal gene program in the heart. Cell Res. 24, 278–292. 10.1038/cr.2014.12. [PubMed: 24481529]
- Lai L, Leone TC, Zechner C, Schaeffer PJ, Kelly SM, Flanagan DP, Medeiros DM, Kovacs A, and Kelly DP (2008). Transcriptional coactivators PGC-1alpha and PGC-lbeta control overlapping programs required for perinatal maturation of the heart. Genes Dev. 22, 1948–1961. 10.1101/ gad.1661708. [PubMed: 18628400]
- Cossette SM, Gastonguay AJ, Bao X, Lerch-Gaggl A, Zhong L, Harmann LM, Koceja C, Miao RQ, Vakeel P, Chun C, et al. (2014). Sucrose non-fermenting related kinase enzyme is essential for cardiac metabolism. Biol. Open 4, 48–61. 10.1242/bio.20149811. [PubMed: 25505152]

- Hansson A, Hance N, Dufour E, Rantanen A, Hultenby K, Clayton DA, Wibom R, and Larsson NG (2004). A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts. Proc. Natl. Acad. Sci. USA 101, 3136–3141. 10.1073/ pnas.0308710100. [PubMed: 14978272]
- Breckenridge RA, Piotrowska I, Ng KE, Ragan TJ, West JA, Kotecha S, Towers N, Bennett M, Kienesberger PC, Smolenski RT, et al. (2013). Hypoxic regulation of hand1 controls the fetalneonatal switch in cardiac metabolism. PLoS Biol. 11, e1001666. 10.1371/journal.pbio.1001666. [PubMed: 24086110]
- Schiff M, Ogier de Baulny H, and Lombès A (2011). Neonatal cardiomyopathies and metabolic crises due to oxidative phosphorylation defects. Semin. Fetal Neonatal Med 16, 216–221. 10.1016/ j.siny.2011.04.002. [PubMed: 21606011]
- Sakamoto T, Matsuura TR, Wan S, Ryba DM, Kim JU, Won KJ, Lai L, Petucci C, Petrenko N, Musunuru K, et al. (2020). A critical role for estrogen-related receptor signaling in cardiac maturation. Circ. Res 126, 1685–1702. 10.1161/CIRCRESAHA.119.316100. [PubMed: 32212902]
- Neary MT, Ng KE, Ludtmann MHR, Hall AR, Piotrowska I, Ong SB, Hausenloy DJ, Mohun TJ, Abramov AY, and Breckenridge RA (2014). Hypoxia signaling controls postnatal changes in cardiac mitochondrial morphology and function. J. Mol. Cell. Cardiol 74, 340–352. 10.1016/ j.yjmcc.2014.06.013. [PubMed: 24984146]
- Guimarães-Camboa N, Stowe J, Aneas I, Sakabe N, Cattaneo P, Henderson L, Kilberg MS, Johnson RS, Chen J, McCulloch AD, et al. (2015). HIF1alpha represses cell stress pathways to Allow proliferation of hypoxic fetal cardiomyocytes. Dev. Cell 33, 507–521. 10.1016/ j.devcel.2015.04.021. [PubMed: 26028220]
- 22. Nau PN, Van Natta T, Ralphe JC, Teneyck CJ, Bedell KA, Caldarone CA, Segar JL, and Scholz TD (2002). Metabolic adaptation of the fetal and postnatal ovine heart: regulatory role of hypoxia-inducible factors and nuclear respiratory factor-1. Pediatr. Res 52, 269–278. 10.1203/00006450-200208000-00021. [PubMed: 12149506]
- 23. Backs J, and Olson EN (2006). Control of cardiac growth by histone acetylation/deacetylation. Circ. Res 93, 15–24. 10.1161/01.RES.0000197782.21444.8f.
- Smith ZD, and Meissner A (2013). DNA methylation: roles in mammalian development. Nat. Rev. Genet 14, 204–220. 10.1038/nrg3354. [PubMed: 23400093]
- Collins HE, and Chatham JC (2020). Regulation of cardiac O-GlcNAcylation: more than just nutrient availability. Biochim. Biophys. Acta, Mol. Basis Dis 1866, 165712. 10.1016/ j.bbadis.2020.165712. [PubMed: 32014551]
- Li J, Johnson JA, and Su H (2018). Ubiquitin and ubiquitin-like proteins in cardiac disease and protection. Curr. Drug Targets 19, 989–1002. [PubMed: 26648080]
- Kamitani T, Kito K, Nguyen HP, and Yeh ET (1997). Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein. J. Biol. Chem 272, 28557–28562. [PubMed: 9353319]
- Kandala S, Kim IM, and Su H (2014). Neddylation and deneddylation in cardiac biology. Am. J. Cardiovasc. Dis 4, 140–158. [PubMed: 25628956]
- Enchev RI, Schulman BA, and Peter M (2015). Protein neddylation: beyond cullin-RING ligases. Nat. Rev. Mol. Cell Biol 16, 30–44. 10.1038/nrm3919. [PubMed: 25531226]
- Petroski MD, and Deshaies RJ (2005). Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol 6, 9–20. 10.1038/nrm1547. [PubMed: 15688063]
- Soucy TA, Dick LR, Smith PG, Milhollen MA, and Brownell JE (2010). The NEDD8 conjugation pathway and its Relevance in cancer biology and Therapy. Genes Cancer 1, 708–716. 10.1177/1947601910382898. [PubMed: 21779466]
- 32. Park HS, Ju UI, Park JW, Song JY, Shin DH, Lee KH, Jeong LS, Yu J, Lee HW, Jeong LS, Yu J, Lee HW, Cho JY, et al. (2016). PPARgamma neddylation essential for adipogenesis is a potential target for treating obesity. Cell Death Differ. 23, 1296–1311. 10.1038/cdd.2016.6. [PubMed: 26990658]
- 33. Zhang X, Zhang YL, Qiu G, Pian L, Guo L, Cao H, Liu J, Zhao Y, Li X, Xu Z, et al. (2020). Hepatic neddylation targets and stabilizes electron transfer flavoproteins to facilitate fatty acid

beta-oxidation. Proc. Natl. Acad. Sci. USA 117, 2473–2483. 10.1073/pnas.1910765117. [PubMed: 31941714]

- 34. Chen W, Luo B, Gao N, Li H, Wang H, Li L, Cui W, Zhang L, Sun D, Liu F, et al. (2021). Neddylation stabilizes Nav1.1 to maintain interneuron excitability and prevent seizures in murine epilepsy models. J. Clin. Invest 131, e136956. 10.1172/JCI136956. [PubMed: 33651714]
- Zhang L, Jing H, Li H, Chen W, Luo B, Zhang H, Dong Z, Li L, Su H, Xiong WC, and Mei L (2020). Neddylation is critical to cortical development by regulating Wnt/beta-catenin signaling. Proc. Natl. Acad. Sci. USA 117, 26448–26459. 10.1073/pnas.2005395117. [PubMed: 33020269]
- 36. Su H, Li J, Zhang H, Ma W, Wei N, Liu J, and Wang X (2015). COP9 signalosome controls the degradation of cytosolic misfolded proteins and protects against cardiac proteotoxicity. Circ. Res 117, 956–966. 10.1161/CIRCRESAHA.115.306783. [PubMed: 26383969]
- 37. Su H, Li J, Osinska H, Li F, Robbins J, Liu J, Wei N, and Wang X (2013). The COP9 signalosome is required for Autophagy, proteasome-mediated Proteolysis, and cardiomyocyte survival in adult mice. Circ. Heart Fail 6, 1049–1057. 10.1161/CIRCHEARTFAILURE.113.000338. [PubMed: 23873473]
- 38. Su H, Li J, Menon S, Liu J, Kumarapeli AR, Wei N, and Wang X (2011). Perturbation of cullin deneddylation via conditional Csn8 ablation impairs the ubiquitin-proteasome system and causes cardiomyocyte necrosis and dilated cardiomyopathy in mice. Circ. Res 103, 40–50. 10.1161/ CIRCRESAHA.110.230607.
- Su H, Li F, Ranek MJ, Wei N, and Wang X (2011). COP9 signalosome regulates autophagosome maturation. Circulation 124, 2117–2128. 10.1161/CIRCULATIONAHA.111.048934. [PubMed: 21986281]
- 40. Li J, Ma W, Li H, Hou N, Wang X, Kim IM, Li F, and Su H (2015). NEDD8 ultimate Buster 1 long (NUB1L) protein suppresses atypical neddylation and promotes the proteasomal degradation of misfolded proteins. J. Biol. Chem 290, 23850–23862. 10.1074/jbc.M115.664375. [PubMed: 26260793]
- Zou J, Ma W, Li J, Littlejohn R, Zhou H, Kim IM, Fulton DJR, Chen W, Weintraub NL, Zhou J, and Su H (2018). Neddylation mediates ventricular chamber maturation through repression of Hippo signaling. Proc. Natl. Acad. Sci. USA 115, E4101–E4110. 10.1073/pnas.1719309115. [PubMed: 29632206]
- 42. Lin Z, von Gise A, Zhou P, Gu F, Ma Q, Jiang J, Yau AL, Buck JN, Gouin KA, van Gorp PRR, et al. (2014). Cardiac-specific YAP activation improves cardiac function and survival in an experimental murine MI model. Circ. Res 115, 354–363. 10.1161/CIRCRESAHA.115.303632. [PubMed: 24833660]
- Muzumdar MD, Tasic B, Miyamichi K, Li L, and Luo L (2007). A global double-fluorescent Cre reporter mouse. Genesis 45, 593–605. 10.1002/dvg.20335. [PubMed: 17868096]
- 44. Guo Y, VanDusen NJ, Zhang L, Gu W, Sethi I, Guatimosim S, Ma Q, Jardin BD, Ai Y, Zhang D, et al. (2017). Analysis of cardiac myocyte maturation using CASAAV, a platform for rapid dissection of cardiac myocyte gene function in vivo. Circ. Res 120, 1874–1888. 10.1161/ CIRCRESAHA.116.310283. [PubMed: 28356340]
- 45. Uosaki H, and Taguchi YH (2016). Comparative gene expression analysis of mouse and human cardiac maturation. Dev. Reprod. Biol 14, 207–215. 10.1016/j.gpb.2016.04.004.
- Ellen Kreipke R, Wang Y, Miklas JW, Mathieu J, and Ruohola-Baker H (2016). Metabolic remodeling in early development and cardiomyocyte maturation. Semin. Cell Dev. Biol 52, 84–92. 10.1016/j.semcdb.2016.02.004. [PubMed: 26912118]
- 47. Cho Y, Tachibana S, Lam K, Arita Y, Khosrowjerdi S, Zhang O, Liang A, Li R, Andreyev A, Murphy AN, and Ross RS (2021). Perm1 promotes cardiomyocyte mitochondrial biogenesis and protects against hypoxia/reoxygenation-induced damage in mice. J. Biol. Chem 297, 100825. 10.1016/j.jbc.2021.100825. [PubMed: 34029594]
- 48. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, et al. (2009). An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732–736. 10.1038/nature07884. [PubMed: 19360080]
- 49. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, Dang CV, and Semenza GL (2007). HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient

renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11, 407–420. 10.1016/ j.ccr.2007.04.001. [PubMed: 17482131]

- Dorn GW 2nd. (2013). Mitochondrial dynamics in heart disease. Biochim. Biophys. Acta 1833, 233–241. 10.1016/j.bbamcr.2012.03.008. [PubMed: 22450031]
- 51. Huang Y, Hickey RP, Yeh JL, Liu D, Dadak A, Young LH, Johnson RS, and Giordano FJ (2004). Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB J 18, 1138–1140. 10.1096/fj.04-1510fje. [PubMed: 15132980]
- 52. Bishop T, and Ratcliffe PJ (2015). HIF hydroxylase pathways in cardiovascular physiology and medicine. Circ. Res 117, 65–79. 10.1161/CIRCRESAHA.117.305109. [PubMed: 26089364]
- Baek K, Scott DC, and Schulman BA (2021). NEDD8 and ubiquitin ligation by cullin-RING E3 ligases. Curr. Opin. Struct. Biol 67, 101–109. 10.1016/j.sbi.2020.10.007. [PubMed: 33160249]
- 54. Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, Fisher RJ, Shoemaker RH, and Melillo G (2005). Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 65, 9047–9055. 10.1158/0008-5472.CAN-05-1235. [PubMed: 16204079]
- 55. Zou J, Ma W, Littlejohn R, Li J, Stansfield BK, Kim IM, Liu J, Zhou J, Weintraub NL, and Su H (2019). Transient inhibition of neddylation at neonatal stage evokes reversible cardiomyopathy and predisposes the heart to isoproterenol-induced heart failure. Am. J. Physiol. Heart Circ. Physiol 316, H1406–H1416. 10.1152/ajpheart.00806.2018. [PubMed: 30925068]
- 56. Fukuda R, Gunawan F, Beisaw A, Jimenez-Amilburu V, Maischein HM, Kostin S, Kawakami K, and Stainier DYR (2017). Proteolysis regulates cardiomyocyte maturation and tissue integration. Nat. Commun 8, 14495. 10.1038/ncomms14495. [PubMed: 28211472]
- 57. Zhou Q, Li H, Li Y, Tan M, Fan S, Cao C, Meng F, Zhu L, Zhao L, Guan MX, et al. (2019). Inhibiting neddylation modification alters mitochondrial morphology and reprograms energy metabolism in cancer cells. JCI Insight 4, e121582. 10.1172/jci.insight.121582. [PubMed: 30668548]
- Lei L, Mason S, Liu D, Huang Y, Marks C, Hickey R, Jovin IS, Pypaert M, Johnson RS, and Giordano FJ (2008). Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein. Mol. Cell Biol 28, 3790–3803. 10.1128/MCB.01580-07. [PubMed: 18285456]
- Hölscher M, Schäfer K, Krull S, Farhat K, Hesse A, Silter M, Lin Y, Pichler BJ, Thistlethwaite P, El-Armouche A, et al. (2012). Unfavourable consequences of chronic cardiac HIF-1alpha stabilization. Cardiovasc. Res 94, 77–86. 10.1093/cvr/cvs014. [PubMed: 22258630]
- 60. Moslehi J, Minamishima YA, Shi J, Neuberg D, Charytan DM, Padera RF, Signoretti S, Liao R, and Kaelin WG Jr. (2010). Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation 122, 1004–1016. 10.1161/ CIRCULATIONAHA.109.922427. [PubMed: 20733101]
- Bekeredjian R, Walton CB, MacCannell KA, Ecker J, Kruse F, Outten JT, Sutcliffe D, Gerard RD, Bruick RK, and Shohet RV (2010). Conditional HIF-1alpha expression produces a reversible cardiomyopathy. PLoS One 5, e11693. 10.1371/journal.pone.0011693. [PubMed: 20657781]
- Romanowicz J, Guerrelli D, Dhari Z, Mulvany C, Reilly M, Swift L, Vasandani N, Ramadan M, Leatherbury L, Ishibashi N, and Posnack NG (2021). Chronic perinatal hypoxia delays cardiac maturation in a mouse model for cyanotic congenital heart disease. Am. J. Physiol. Heart Circ. Physiol 320, H1873–H1886. 10.1152/ajpheart.00870.2020. [PubMed: 33739154]
- Ryu JH, Li SH, Park HS, Park JW, Lee B, and Chun YS (2011). Hypoxia-inducible factor alpha subunit stabilization by NEDD8 conjugation is reactive oxygen species-dependent. J. Biol. Chem 286, 6963–6970. 10.1074/jbc.M110.188706. [PubMed: 21193393]
- 64. Curtis VF, Ehrentraut SF, Campbell EL, Glover LE, Bayless A, Kelly CJ, Kominsky DJ, and Colgan SP (2015). Stabilization of HIF through inhibition of Cullin-2 neddylation is protective in mucosal inflammatory responses. Faseb j 29, 208–215. 10.1096/fj.14-259663. [PubMed: 25326537]

- 65. Heir P, Sufan RI, Greer SN, Poon BP, Lee JE, and Ohh M (2013). DCNL1 functions as a substrate sensor and activator of cullin 2-RING ligase. Mol. Cell Biol 33, 1621–1631. 10.1128/ mcb.01342-12. [PubMed: 23401859]
- 66. Ehrentraut SF, Kominsky DJ, Glover LE, Campbell EL, Kelly CJ, Bowers BE, Bayless AJ, and Colgan SP (2013). Central role for endothelial human deneddylase-1/SENP8 in fine-tuning the vascular inflammatory response. J. Immunol 190, 392–400. 10.4049/jimmunol.1202041. [PubMed: 23209320]
- Leidecker O, Matic I, Mahata B, Pion E, and Xirodimas DP (2012). The ubiquitin E1 enzyme Ube1 mediates NEDD8 activation under diverse stress conditions. Cell Cycle 11, 1142–1150. 10.4161/cc.11.6.19559. [PubMed: 22370482]
- Hjerpe R, Thomas Y, and Kurz T (2012). NEDD8 overexpression results in neddylation of ubiquitin substrates by the ubiquitin pathway. J. Mol. Biol 421, 27–29. 10.1016/j.jmb.2012.05.013. [PubMed: 22608973]
- Lobato-Gil S, Heidelberger JB, Maghames C, Bailly A, Brunello L, Rodriguez MS, Beli P, and Xirodimas DP (2021). Proteome-wide identification of NEDD8 modification sites reveals distinct proteomes for canonical and atypical NEDDylation. Cell Rep. 34, 108635. 10.1016/ j.celrep.2020.108635. [PubMed: 33472076]
- 70. Vogl AM, Phu L, Becerra R, Giusti SA, Verschueren E, Hinkle TB, Bordenave MD, Adrian M, Heidersbach A, Yankilevich P, et al. (2020). Global site-specific neddylation profiling reveals that NEDDylated cofilin regulates actin dynamics. Nat. Struct. Mol. Biol 27, 210–220. 10.1038/ s41594-019-0370-3. [PubMed: 32015554]
- 71. Liu J, Wen T, Dong K, He X, Zhou H, Shen J, Fu Z, Hu G, Ma W, Li J, et al. (2021). TEAD1 protects against necroptosis in postmitotic cardiomyocytes through regulation of nuclear DNAencoded mitochondrial genes. Cell Death Differ. 28, 2045–2059. 10.1038/s41418-020-00732-5. [PubMed: 33469230]
- 72. Xin M, Kim Y, Sutherland LB, Murakami M, Qi X, McAnally J, Porrello ER, Mahmoud AI, Tan W, Shelton JM, et al. (2013). Hippo pathway effector Yap promotes cardiac regeneration. Proc. Natl. Acad. Sci. USA 110, 13839–13844. 10.1073/pnas.1313192110. [PubMed: 23918388]
- 73. Kondo K, Klco J, Nakamura E, Lechpammer M, and Kaelin WG Jr. (2002). Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237–246. 10.1016/s1535-6108(02)00043-0. [PubMed: 12086860]
- 74. Emerling BM, Weinberg F, Liu JL, Mak TW, and Chandel NS (2008). PTEN regulates p300dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc. Natl. Acad. Sci. USA 105, 2622–2627. 10.1073/pnas.0706790105. [PubMed: 18268343]
- 75. Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, Howard TP, Takeda DY, Ly SH, Kim E, et al. (2018). Mutational processes shape the landscape of TP53 mutations in human cancer. Nat. Genet 50, 1381–1387. 10.1038/s41588-018-0204-y. [PubMed: 30224644]
- Vordermark D, Shibata T, and Brown JM (2001). Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formation. Neoplasia 3, 527–534. 10.1038/sj.neo.7900192. [PubMed: 11774035]
- 77. Pirone L, Xolalpa W, Sigursson JO, Ramirez J, Pérez C, González M, de Sabando AR, Elortza F, Rodriguez MS, Mayor U, et al. (2017). A comprehensive platform for the analysis of ubiquitin-like protein modifications using in vivo biotinylation. Sci. Rep 7, 40756. 10.1038/srep40756. [PubMed: 28098257]
- 78. Pang Z, Chong J, Zhou G, de Lima Morais DA, Chang L, Barrette M, Gauthier C, Jacques PÉ, Li S, and Xia J (2021). MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 49, W388–W396. 10.1093/nar/gkab382. [PubMed: 34019663]
- 79. Wei S, Guo A, Chen B, Kutschke W, Xie YP, Zimmerman K, Weiss RM, Anderson ME, Cheng H, and Song LS (2010). T-tubule remodeling during transition from hypertrophy to heart failure. Circ. Res 107, 520–531. 10.1161/CIRCRESAHA.109.212324. [PubMed: 20576937]

## Highlights

• Inhibition of neddylation in the developing heart causes heart failure

- Neddylation is required for cardiomyocyte maturation
- Neddylation regulates cardiomyocyte perinatal metabolic reprogramming
- Neddylation targets HIF1a and promotes fatty acid utilization in cardiomyocytes





(A) Scheme depicting experimental timeline. Neonatal NAE1<sup>Flox/+</sup> and NAE1<sup>Flox/Flox</sup> pups carrying the mTmG reporter were injected with AAV9-cTnT-Cre at high (HD), medium (MD), and low (LD) doses subcutaneously and subjected to echocardiography (Echo) and tissue collection at indicated times.

(B) Representative confocal images of mGFP<sup>+</sup> (mG) and mtdTomato<sup>+</sup> (mT) CMs in the heart 4 weeks post AAV injection. Part of the ventricular myocardium (top, scale bar, 300  $\mu$ m) and enlarged box areas (bottom, scale bar, 50  $\mu$ m) are shown.

(C) Quantification of the percentage of  $mGFP^+$  CMs in AAV-infected hearts; n = 8 fields from three hearts/dose.

(D) Quantitative real-time PCR analysis of indicated genes in hearts of 4-week-old mice receiving HD AAVs; n = 8 vs. 3.

(E and F) Western blot analysis (E) and quantification (F) of indicated proteins in hearts of 4-week-old mice infected with HD or MD AAVs; n = 4 vs. 4 vs. 4.

(G) Echocardiography showing temporal changes in ejection fraction (EF) and fractional shortening (FS) in mice receiving HD AAVs; n = 7 vs. 4.

(H) Echocardiography B-mode images in 6-week-old mice post HD AAV injection. Double-headed arrows mark the ventricular chamber diameter at systole and diastole, respectively.(I) Gross morphology of 6-week mouse hearts infected with HD AAVs. Scale bar, 5 mm.

(J) Heart weight (HW)-to-body weight (BW) ratio and lung weight-to-BW ratio; n = 8 vs. 4.

(K) Ventricular chamber size and wall thickness at 6 weeks post HD AAV injection; n =

7 vs. 4. LVID, left-ventricle (LV) internal diameter; LVPW, LV posterior wall thickness; d, diastolic state; s, systolic state. \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001; \*\*\*\*p < 0.0001; NS, not significant.

Error bars indicate SEM. For (F), two-way ANOVA followed by multiple comparison was performed. All other statistical analysis was performed by one-way ANOVA followed by multiple comparison.

Zou et al.

Page 26





(A) *In situ* confocal imaging of surface myocardium in FM 4-64FX-stained 4-week-old NAE1<sup>F/F</sup> hearts infected with LD AAVs. Boxed areas from  $mT^+$  (1) and  $mG^+$  (2) CMs are enlarged to show T-tubule patterns.

(B) Histogram of fluorescence intensity of the yellow line-marked regions in boxed areas in (A), scale bar, 20  $\mu$ m. Note the overlap of FM 4-64FX signals (blue) with mT (red) and mG (green) signals.

(C) Quantification of T-tubule contents in  $mT^+$  and  $mG^+$  CMs in hearts of 4-week-old NAE1<sup>F/F</sup> mice infected with LD AAVs.

(D) *In situ* confocal imaging of surface myocardium from hearts of 4-week-old NAE1<sup>F/+</sup> and NAE1<sup>F/F</sup> mice infected with LD AAVs. Scale bar, 20  $\mu$ m. Boxed areas are enlarged and shown at bottom.

(E and F) Quantification of T-tubule integrity (E) and regularity (F).

(G) Cell size and geometry of CMs isolated from 4-week-old mouse hearts infected with LD AAVs.

(H) Quantitative real-time PCR analysis of indicated genes in hearts from 4-week-old mice infected with MD AAVs.

(I) Western blot analysis of indicated proteins in hearts from 4-week-old mice infected with MD AAVs.

(J) Ratios of the adult to fetal isoforms of the indicated proteins in (I). p < 0.05; p < 0.01; p < 0.001; p < 0.001; p < 0.001. Error bars indicate SEM.

For violin plots in (C), (E), (F), and (G), n = 120 vs. 120 fields of view within n = 3 vs. 3 biological replicates, analyzed by unpaired Student's t test. For (H), n = 4 vs. 4 biological replicates. For (J), n = 5 vs. 5 biological replicates. Statistical analysis was by one-way ANOVA followed by multiple comparison.



Figure 3. Transcriptome analysis reveals metabolic derangement in neonatal NAE1-deficient heart

(A) Scheme showing experiment design.

(B) Principal-component analysis (PCA) of RNA-seq replicates.

(C) Volcano plot showing significantly downregulated (blue) and upregulated (red) genes in hearts from NAE1<sup>CKO</sup> mice (fold change [FC] > 1.5 or <-1.5 and  $p_{adj}$  <0.05).

(D) Ratios of fetal to adult isoforms in neonatal hearts from control and NAE1<sup>CKO</sup> mice (from RNA-seq data); n = 4 vs. 4 biological replicates.

(E and F) Gene set enrichment analysis of immature (E) and mature (F) gene sets.

(G) Gene set enrichment analysis of differentially expressed genes in hearts from NAE1<sup>CKO</sup> mice showed enrichment of the indicated KEGG pathways.

(H) Bar graphs showing dysregulation of the indicated metabolic genes in hearts from NAE1<sup>CKO</sup> mice.

(I) Chord plots showing enrichment of dysregulated metabolic genes in the PPAR and HIF1 $\alpha$  signaling pathways. \*\*p < 0.01. Error bars indicate SEM.

For (D), one-way ANOVA followed by multiple comparison was performed.



## Figure 4. Fatty acid metabolic and mitochondrial dysfunction in hearts from NAE1-deficient mice

(A–F) Hearts from 4-week-old mice receiving MD AAVs at P0 were used for the analyses. (A) Quantitative real-time PCR analysis of indicated metabolic genes; n = 4 vs. 4. (B and C) Western blots (B) and quantification (C; n = 8 vs. 4) of indicated proteins. (D and E) Seahorse analysis of CMs isolated from hearts of 4-week-old mice. Oxygen consumption rate (OCR) (D) and quantification of basal respiration, maximal respiration, and non-mitochondrial oxygen consumption are shown (E); n = 6 vs. 6. (F) ATP content of indicated heart tissues per gram protein; n = 3 vs. 3.

(G and H) Hearts from neonatal CTL and NAE1<sup>CKO</sup> mice at P1 were subjected to the analyses. (G) Quantitative real-time PCR analysis of the indicated genes; n = 4 vs. 3. (H) Transmission electron microscopy (TEM) images. Boxed areas are enlarged in (a)–(f) to show mitochondrial structures. Arrows mark mitochondria with loose cristae; arrowheads point to mitophagic vesicles; yellow D indicates degenerating mitochondria. Scale bar, 1  $\mu$ m. (I) Quantification of the percentage of mitochondria with loose cristae or mitophagic vesicles; n = 7 vs. 6. \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001; \*\*\*\*p < 0.0001. Error bars indicate SEM. All statistical analyses were performed by one-way ANOVA followed by multiple comparison.





(A–F) NRVCs were treated with siRNA against luciferase (siLuci) or co-transfection with siRNAs against NAE1 and UBA3 (siNAE) or siLuci followed by treatment with MLN4924 (MLN, 1  $\mu$ M) for 48 h. (A) Western blots of the indicated proteins. NEDD8 blots with short or long exposure (exp.) time are shown. (B) Identification of lipid droplets in NRVCs by LipidTOX (left, green) and BODIPY (right, green) staining. Phalloidin (red) and DAPI (blue) were counterstained to identify cardiomyocytes and nucleus, respectively. Scale bar, 30  $\mu$ m. (C) Quantification of LipidTOX and BODIPY fluorescence intensity per cell; n =

6 replicates/group. (D) Quantification of triglyceride (TG) levels; n = 3 replicates/group. (E and F) Seahorse analysis of oxygen consumption rate (OCR) (E) and quantification (F) of basal and maximal respiration (Resp.); n = 7 replicates/group.

(G and H) Fatty acid oxidation assay by Seahorse analysis of OCR (G) and quantification (H) of basal respiration (Basal), maximal respiration (Maxi), and acute response ( $OCR_{2nd \ stage} - OCR_{first \ stage}$ ). Etomoxir (Eto), a CPT1a inhibitor, was used to inhibit fatty acid utilization; n = 4 replicates/group.

(I) Quantitative real-time PCR analysis of the indicated genes in NRVCs treated with or without MLN (1  $\mu$ M) for 48 h and oleic acid (OA; 100 mM) for 24 h; n = 3 replicates/ group. \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001; \*\*\*\*p < 0.0001. Error bars indicate SEM. All statistical analyses were performed by one-way ANOVA followed by multiple comparison.





(A) Venn diagram (top) of differentially expressed genes in hearts from NAE1<sup>CKO</sup> mice and HIF1a. ChIP-seq analysis and Gene Ontology analysis (bottom) of the 155 overlapping genes.

(B) Heatmap showing the expression levels of selected genes in glycolysis, fatty acid oxidation, and mitochondria among the overlapping genes.

(C) Quantitative real-time PCR analysis of HIF1 $\alpha$  transcripts in neonatal mouse hearts; n = 4 vs. 3.

(D) Western blots of the indicated proteins in neonatal mouse hearts.

(E) Confocal images of E14.5 myocardium cryosections immunostained with antibody against HIF1 $\alpha$ . Yellow arrows mark nuclei with enriched HIF1 $\alpha$  staining. Scale bars, 30 µm. (F) Quantification of relative HIF1 $\alpha$  fluorescence intensity and of relative HIF1 $\alpha$  fluorescence intensity in the nuclei; n = 5 vs. 5.

(G) Confocal images of E14.5 myocardium cryosections immunostained with antibody against Glut1. Scale bar,  $30 \mu m$ .

(H) Quantification of overall relative Glut1 fluorescence intensity in hearts from control (CTL) and NAE1<sup>CKO</sup> mice, as well as Glut1 fluorescence intensity in mT<sup>+</sup> CMs and mG<sup>+</sup> CMs in hearts from NAE1<sup>CKO</sup> mice; n = 6 vs. 6.

(I and J) Western blots (I) and quantification (J) of HIF1 $\alpha$  expression in hearts of 4-weekold indicated mice infected with high dose (HD) of AAVs; n = 8 vs. 4.

(K) Quantitative real-time PCR analysis of the indicated genes in hearts of 4-week-old mice infected with HD AAVs; n = 3 vs. 5. \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001; \*\*\*\*p < 0.0001; ns, not significant. Error bars indicate SEM. All statistical analyses were performed by one-way ANOVA followed by multiple comparison.

Page 36



#### Figure 7. Neddylation of HIF1a regulates its expression

(A) Western blot of the indicated proteins in NRVCs treated with bortezomib (BZM; 100 nM) and/or MLN (1  $\mu$ M) for 24 h under normoxic or hypoxic conditions. Densitometry of HIF1a is shown below the blot.

(B) Immunoprecipitation of HIF1a and immunoblotting of the indicated proteins in HEK293 cells transfected with the indicated plasmids.

(C) Affinity purification of biotinylated neddylated proteins in HEK293 cells transfected with the indicated plasmids, followed by immunoblotting of the indicated proteins.

(D) Western blots of the indicated proteins. NRVCs were transfected with siRNA targeting luciferase control (Luci) or cullin 2 (Cul2) for 48 h, followed by BZM (100 nM) or MLN (1  $\mu$ M) treatment for an additional 24 h

(E) Western blot of the indicated proteins. NRVCs were transfected with siRNA targeting Luci or Cul2 for 48 h and then treated with MLN for the indicated times.

(F) Representative images of LipidTOX staining. Scale bars, 50  $\mu$ m. NRVCs were treated with MLN for 48 h before being incubated with oleic acid (OA; 100 mM) in the presence or absence of echinomycin (ECH) for an additional 24 h.

(G) Triglyceride (TG) content in NRVCs treated under the same conditions as in (F); n = 3 replicates/group.

(H) A proposed model. Neddylation regulates CM maturation and postnatal cardiac development by mediating metabolic transition in part in an HIF1 $\alpha$ -dependent manner. \*\*\*p < 0.001; \*\*\*\*p < 0.0001. Error bars indicate SEM.

Statistical analysis in (G) was performed by two-way ANOVA followed by multiple comparison.

#### KEY RESOURCES TABLE

| REAGENT or RESOURCE                           | SOURCE  | IDENTIFIER                 |
|---|---|----------------------------|
| Antibodies                                    |   |                            |
| NAE1  | Cell Signaling Technology                       | Cat# 14321                 |
| NEDD8   | Cell Signaling Technology                       | Cat#2754                   |
| CUL2  | Thermo Fisher Scientific                        | Cat# 51-1800               |
| МҮН6  | Proteintech                                     | Cat# 2281-1-Ap             |
| MYH7  | Proteintech                                     | Cat# 22280-1-ap            |
| MYL2  | Proteintech                                     | Cat# 10906-1-AP            |
| MYL7  | Proteintech                                     | Cat#17283-1-AP             |
| Kir2.1  | Thermo Fisher Scientific                        | Cat# MA5-27681             |
| HCN4  | Thermo Fisher Scientific                        | Cat#MA3-903                |
| ACSL1   | Thermo Fisher Scientific                        | Cat# PA5-17136             |
| Bacterial and virus strains                   |   |                            |
| pEN.AAV9-cTnt-Cre-WPRE                        | Vigene Biosciences                              | AAV9SP(VB210825-1182agk)-C |
| Chemicals, peptides, and recombinant proteins |   |                            |
| Chemical: MLN4924                             | Active Biochem                                  | N/A                        |
| Chemical: bortezomib                          | Enzo Life Science                               | N/A                        |
| Chemical: Echinomycin                         | Sigma-Aldrich                                   | Cat# SML0477               |
| Critical commercial assays                    |   |                            |
| ATP Bioluminescent Assay Kit                  | Sigma   | Cat# FL-AA                 |
| Lipofectamine RNAimax                         | Thermo Fisher Scientific                        | Cat# 13778150              |
| LipidTOX kit                                  | Thermo Fisher Scientific                        | Cat# H34475                |
| Infinity Triglycerides kit                    | Thermo Fisher Scientific                        | Cat# TR22421               |
| Dual-Luciferase® Reporter Assay System        | Promega   | Cat# E1910                 |
| Plasmid Maxi kit                              | Qiagen  | Cat# 12162                 |
| TRIzol RNA isolation kit                      | Invitrogen                                      | Cat# 15596026              |
| Deposited data                                |   |                            |
| NAE1CKO RNA-seq analysis                      | Gene Expression Ominibus                        | GSE217964                  |
| Experimental models: Cell lines               |   |                            |
| HEK293 cell line                              | ATCC  | Cat# CRL-1573              |
| Experimental models: Organisms/strains        |   |                            |
| Transgenic mouse line: NAE1 <sup>Flox</sup>   | Previously generated by ourselves <sup>41</sup> | N/A                        |
| Transgenic mouse line: aMHC <sup>Cre</sup>    | Jackson Laboratory                              | Cat# 011038                |
| Transgenic mouse line: Rosa26 <sup>mTmG</sup> | Jackson Laboratory                              | Cat# 007676                |

| REAGENT or RESOURCE  | SOURCE  | IDENTIFIER           |
|--|---|----------------------|
| Oligonucleotides   |   |                      |
| siRNAs against rat Cul2 (5' – TTCGAGCGACCAGTAACCTTA-3')        | Qiagen  | Cat# SI01787443      |
| siRNAs against luciferase (5' -AACGTACGCGGAATACTTCGA-3')       | Qiagen <sup>41</sup>  | N/A                  |
| qPCR primer: Nae1, Sense, "CAACTCAGATCCCAAGCAGTAT"             | Integrated DNA Technologies                                     | N/A                  |
| qPCR primer: Nae1, Anti-sense,<br>"CCTTTAAGGCACGAGCTAGAA"      | Integrated DNA Technologies                                     | N/A                  |
| qPCR primer: Serca2a, Sense, "CCTCCACTTCCTCATCCTCTAT "         | Integrated DNA Technologies                                     | N/A                  |
| qPCR primer: Serca2a, Anti-sense,<br>"GATGACTGGCAGTGAGATCTTG " | Integrated DNA Technologies                                     | N/A                  |
| qPCR primer: Nppa, Sense, "CACAGATCTGATGGATTTCAAGA"            | Integrated DNA Technologies                                     | N/A                  |
| qPCR primer: Nppa, Anti-sense, "CCTCATCTTCTACCGGCATC"          | Integrated DNA Technologies                                     | N/A                  |
| qPCR primer: Nppb, Sense, "GTCAGTCGTTTGGGCTGTAAC"              | Integrated DNA Technologies                                     | N/A                  |
| qPCR primer: Nppb, Anti-sense, "AGACCCAGGCAGAGTCAGAA"          | Integrated DNA Technologies                                     | N/A                  |
| Recombinant DNA  |   |                      |
| HA-HIF1a plasmid   | Kondo et al. <sup>73</sup>                                      | Addgene, Cat #18949  |
| HRE-luciferase   | Emerling et al. <sup>74</sup>                                   | Addgene, Cat #26731  |
| Renilla luciferase   | Giacomelli et al.75   | Addgene, Cat #118016 |
| 5HRE-GFP   | Vordermark et al. <sup>76</sup>                                 | Addgene, Cat #46926  |
| pShuttle-CMV-FLAG-NEDD8  | Previously generated by us(Zou et al. <sup>41</sup> )           | N/A                  |
| pShuttle-CMV-FLAG-NEDD8-dGG                                    | Previously generated by us <sup>41</sup>                        | N/A                  |
| CAG X-bioNEDD8-BirAOV5-g2A-puro                                | kind gift from James Sutherland at CIC bioGUNE <sup>77</sup>    | N/A                  |
| CAG X -bioNEDD8-BirAOV5-g2A -UBC12                             | kind gift from James Sutherland<br>at CIC bioGUNE <sup>77</sup> | N/A                  |
| Software and algorithms  |   |                      |
| MetaboAnalyst 5.0 platform                                     | Public available by Xia Lab <sup>78</sup>                       | N/A                  |
| Microsoft Office   | Microsoft   | N/A                  |
| Photoshop  | Adobe   | N/A                  |
| Illustrator  | Adobe   | N/A                  |
| Endnote 20   | Clarivate   | N/A                  |
| GraphPad Prism 9   | Dotmatics   | N/A                  |